To test the efficacy of of Yumanity’s Stearyl-CoA desaturase (SCD) inhibitors YTX-7739 and YTX-9184 in immunocompetent models of glioblastoma (GBM) and identify relevant immunotherapeutic combinations that may synergize with SCD inhibitors.
|Effective start/end date||10/1/21 → 9/30/23|
- Proteostasis Therapeutics, Inc. (Agmt 12/16/2021 PO 19386)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.